September 28, 2017

Magenta Medical Secures Funding for Development of Therapies for Acute Heart Failure

September 28, 2017—Magenta Medical, an Israel-based company developing therapeutic approaches to the management and treatment of acute heart failure, announced the closing of its $15 million Series B financing round. The funding will support the expansion and acceleration of the clinical program toward approval in Europe and a pivotal study in the United States.

The syndicate of investors is comprised of Abiomed, Inc., as well as Pitango Venture Capital, JAFCO Co. Ltd., and a group of industry leaders and cardiovascular experts led by Prof. Jacques Seguin, MD, who is joining Magenta's Board of Directors after the closing. Magenta Medical was founded in October 2012 by Prof. Ehud Schwammenthal, MD, and Yosi Tuval.


October 2, 2017

Enrollment Completed in Pivotal Trial of Essential Medical's Manta Large-Bore Vascular Closure Device

September 27, 2017

Medtronic's HeartWare HVAD System Approved for Destination Therapy